$GUTS News

Fractyl Health, Inc. (GUTS) Discusses Commercialization Strategy for Investigational Post-GLP-1 Procedural Therapy Transcript

Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial

Fractyl Health, Inc. Common Stock Q2 2026 Earnings Call Summary

Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ...

Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript

Fractyl Health Q2 Earnings Call Highlights

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate

Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

Fractyl Health to Participate in Upcoming Investor Events

Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript

Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars

Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Fractyl Health Announces One-Year Results From Its REMAIN-1 Midpoint Cohort; Results Reinforce Potential Of Revita DMR System To Become First Durable Therapy For Post-GLP-1 Weight Maintenance

Fractyl Health (GUTS) Stock Sees Fair Value Cut As Analysts Weigh Revita Opportunity

Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At Funding

HC Wainwright & Co. Reiterates Buy on Fractyl Health, Maintains $8 Price Target